Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Im, Seock-Ah, Xu, Binghe, Li, Wei, Robson, Mark, Ouyang, Quchang, Yeh, Dah-Cherng, Iwata, Hiroji, Park, Yeon Hee, Sohn, Joo Hyuk, Tseng, Ling-Ming, Goessl, Carsten, Wu, Wenting, Masuda, Norikazu
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7260217/
https://ncbi.nlm.nih.gov/pubmed/32472001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-63033-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares